Home » Newsletters » BioWorld Science

BioWorld Science

May 18, 2007

View Archived Issues

Safety and immunogenicity of new oral vaccine against enterotoxigenic E. coli demonstrated in humans

Novel nanoparticle-based technology ensures effective delivery of therapeutic siRNA in vivo

Dose-escalation trial to establish optimal dose of AL-02

Recent patents disclose novel treatment options for cardiovascular disorders

Recent University of Pittsburgh patent reports novel diagnostic agents for Alzheimer's disease

Recent patents impart new therapeutic agents for cancer

Incyte recaps active quarter

Organon's natural estrogen contraceptive enters phase III trials

Update on Peptech and EvoGenix merger

Phase III Revlimid trial halted based on positive findings

Telomerase activator shows beneficial effects on human aging

Cyto Pulse and KCC develop DNA vaccine for prostate application

Tsumura discontinues development of TU-025 in U.S.

Patient enrollment completed in phase III trial of pirfenidone in IPF patients

Medarex and Organon announce therapeutic antibody collaboration

QuatRx licenses becocalcidiol to CollaGenex

Next-generation nasal spray flu vaccine enters phase I trial

CF-101 enters clinic for third therapeutic indication

Efficacy and MOA of BioLineRx's BL-1020 for schizophrenia sought in clinic

Fast track designation received for romidepsin

Sirion commences phase III evaluation of two of its compounds

Tapestry Pharmaceuticals reports update on next-generation taxane

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 31, 2026.
AIDS 2026: New targets for metabolic dysfunction despite ART
BioWorld
Although antiretroviral therapy (ART) can suppress HIV to undetectable levels, a growing body of evidence suggests that the virus leaves a lasting biological...
Tuojie Biotech (Shanghai) synthesizes new SARM1 inhibitors
BioWorld Science
Tuojie Biotech (Shanghai) Co. Ltd. has prepared and tested NAD(+) hydrolase SARM1 (SAMD2; MyD88-5) inhibitors found to be potentially useful for the treatment of...
Jingxin discloses new muscarinic and sigma receptor agonists
BioWorld Science
Shanghai Jingxin Biopharmaceutical Co. Ltd. and Zhejiang Jingxin Pharmaceutical Co. Ltd. have synthesized new muscarinic acetylcholine receptor and sigma receptor...
Death in Chinese gene-editing trial exposes ethical fault lines
BioWorld
The death of a 6-year-old girl after receiving an experimental brain-directed gene-editing therapy at the Xinhua Hospital in Shanghai has reopened debate over how...